What is HC Wainwright’s Forecast for ENTA Q1 Earnings?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research report issued to clients and investors on Tuesday, December 24th. HC Wainwright analyst E. Arce expects that the biotechnology company will earn ($1.18) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.45) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.54) EPS, FY2026 earnings at ($7.90) EPS, FY2027 earnings at ($8.00) EPS and FY2028 earnings at ($7.36) EPS.

Other equities research analysts have also recently issued research reports about the stock. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $6.00 on Friday. Enanta Pharmaceuticals has a 1 year low of $5.70 and a 1 year high of $17.80. The firm has a market cap of $127.16 million, a price-to-earnings ratio of -1.09 and a beta of 0.49. The company has a 50-day moving average of $9.28 and a 200 day moving average of $11.53.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same quarter last year, the company posted ($1.33) EPS. Enanta Pharmaceuticals’s revenue for the quarter was down 22.8% compared to the same quarter last year.

Institutional Trading of Enanta Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its position in Enanta Pharmaceuticals by 4.7% during the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 1,548 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $35,000. US Bancorp DE boosted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Enanta Pharmaceuticals by 35.4% in the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after acquiring an additional 7,287 shares during the period. Finally, Quest Partners LLC increased its position in Enanta Pharmaceuticals by 65.0% during the third quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 7,535 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 13.64% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.